Yesterday I watched what I considered to be an historic FDA advisory committee meeting reviewing data supporting the approval of Entasis-Innoviva’s drug sulbactam-durlobactam (Sul-Duro) in the treatment of hospital acquired pneumonia caused by highly resistant strains of Acinetobacter. In today’s blog I would like to discuss several aspects of this important event.
Entasis Scores. Now What?
Entasis Scores. Now What?
Entasis Scores. Now What?
Yesterday I watched what I considered to be an historic FDA advisory committee meeting reviewing data supporting the approval of Entasis-Innoviva’s drug sulbactam-durlobactam (Sul-Duro) in the treatment of hospital acquired pneumonia caused by highly resistant strains of Acinetobacter. In today’s blog I would like to discuss several aspects of this important event.